Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Why It Matters

The data position Pharvaris as a potential first‑in‑class oral therapy for bradykinin‑mediated angioedema, a market dominated by injectables, and could unlock significant revenue if regulatory approvals are secured. Investors will watch the upcoming NDA and CHAPTER‑3 readout as key catalysts for valuation uplift.

Key Takeaways

• Phase 3 RAPIDe‑3 met all efficacy endpoints
• NDA for deucrictibant IR targeted H1 2026
• CHAPTER‑3 topline data expected Q3 2026
• Cash balance reached €292M (~$315M)
• R&D spend rose to €124M (~$134M)

Pulse Analysis

Pharvaris is tackling a clear therapeutic gap in hereditary and acquired angioedema by developing oral bradykinin B2 receptor antagonists. Current standards rely on injectable biologics, which limit patient convenience and adherence. The RAPIDe‑3 trial demonstrated rapid symptom relief—median onset in 1.28 hours and full resolution in under 12 hours—suggesting deucrictibant could deliver injectable‑like efficacy with the ease of a pill. This differentiation is especially valuable for patients who experience frequent attacks and seek on‑demand treatment without the logistical hurdles of injections.

Regulatory momentum is building around Pharvaris’ pipeline. Deucrictibant has earned orphan‑drug designation from the FDA, European Commission, and Swissmedic, streamlining the path to market. The company aims to file a U.S. NDA for the immediate‑release formulation in the first half of 2026, leveraging the robust RAPIDe‑3 data. Simultaneously, the CHAPTER‑3 prophylaxis study, which enrolled 81 participants, will deliver topline results in Q3 2026, and the long‑term CHAPTER‑4 extension is already underway. These milestones position Pharvaris to address both acute and preventive needs across multiple angioedema subtypes, potentially expanding its addressable market beyond HAE type 1 and 2.

Financially, Pharvaris ended 2025 with €292 million (≈$315 million) in cash, providing a runway to fund ongoing trials and the anticipated NDA submission. R&D expenses rose to €124 million (≈$134 million) for the year, reflecting intensified trial activity, while G&A costs remained stable. Although the FY loss widened to €176 million (≈$190 million), the company’s disciplined capital management and upcoming data readouts are expected to attract further investment. Participation in high‑profile investor conferences this spring underscores management’s confidence in the pipeline’s commercial potential, making Pharvaris a biotech to watch in the oral angioedema space.